Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
- None.
- None.
Insights
The preclinical data presented by Absci Corporation for their anti-TL1A antibody program, ABS-101, indicate a strategic move towards developing a potentially superior therapeutic option in the biopharmaceutical market. The use of generative AI in drug discovery, particularly in optimizing leads with subnanomolar affinity, represents an innovative approach that could significantly reduce the time and cost associated with traditional drug development processes. The emphasis on potency, developability and an extended half-life for subcutaneous dosing could position ABS-101 favorably against competitors, potentially leading to a more convenient treatment regimen for patients.
From a medical research perspective, the success of these preclinical studies is crucial as they lay the groundwork for the safety and efficacy profiles of new drug candidates. The move towards IND submission and Phase 1 trials is a pivotal step and if successful, could disrupt current treatment paradigms. However, it is important to note that the transition from preclinical to clinical stages is fraught with challenges and many candidates fail to demonstrate the same promise in human trials as they do in preclinical assessments.
Investors and stakeholders in the biotech sector closely monitor the progress of preclinical studies, particularly when they involve advanced technologies like AI-driven drug discovery. Absci's announcement regarding ABS-101 could influence market perceptions of the company's technological capabilities and pipeline potential. The biotech industry is known for its high-risk, high-reward nature and advancements to clinical stages can significantly impact a company's valuation.
Given the projected timeline for IND submission and Phase 1 trials, investors will be attuned to the company's ability to adhere to these timelines and the outcomes of these early-stage trials. The potential of ABS-101 to become a best-in-class drug also opens up market opportunities that Absci could capitalize on, provided the subsequent clinical trials yield positive results. It is imperative for investors to consider the inherent risks of drug development, regulatory hurdles and the competitive landscape when evaluating the long-term potential of Absci's pipeline.
The biotech industry is increasingly integrating AI to enhance drug discovery and Absci's use of its Integrated Drug Creation™ platform to generate over 50 antibody leads is a testament to this trend. The selection of three candidates for the ABS-101 program based on AI lead optimization is noteworthy, as it demonstrates the practical application of AI in streamlining the drug development process. The potential best-in-class designation for ABS-101 hinges on its ability to outperform existing and developmental treatments in terms of efficacy, safety and patient convenience.
While the preclinical results are promising, it is important to contextualize these findings within the broader industry. Many biotech firms are pursuing similar AI-driven strategies and the landscape is competitive. The ability of Absci to leverage its AI platform to rapidly progress from preclinical studies to IND submissions could give it a competitive edge, but the true test will come with clinical trial results and regulatory approvals. The long-term success of ABS-101 will depend on its clinical performance, scalability of production and market acceptance.
Preclinical data support profile for development of a potential best-in-class drug
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
VANCOUVER, Wash. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be presenting positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program, this week at the 42nd Annual J.P. Morgan Healthcare Conference.
Absci’s Integrated Drug Creation™ platform designed over 50 antibody leads with subnanomolar affinity using its de novo generative AI foundation model, enabling a diversity of potential candidates. Absci has selected three potential candidates for the ABS-101 program utilizing its AI lead optimization capabilities.
In preclinical studies, ABS-101 potential candidates exhibited properties consistent with a potentially superior product profile by demonstrating equal or superior potency data from multiple biophysical and cellular assays, in addition to improved developability properties, as compared to estimated performance of a putative clinical competitor molecule in later stages of development. These attributes support the program’s potential to create an efficacious candidate conducive to subcutaneous dosing. Furthermore, in vitro and preliminary in vivo PK studies confirm the potential for extended half-life, supporting the objective for significantly improved dosing intervals.
These preclinical results demonstrate the ability of Absci’s generative AI platform to rapidly and efficiently create differentiated antibody drug candidates. Supporting data for these assessments can be found in the associated company presentation for the upcoming J.P. Morgan Healthcare Conference, published on Absci’s investor relations website.
Absci expects to initiate Investigational New Drug application (IND) enabling studies for ABS-101 in February 2024, and submit an IND in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
Absci management is scheduled to present these data, and other corporate updates, on Thursday, January 11th at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding timing of IND submission for ABS-101 and Phase 1 trials thereafter; the significance of preclinical results for ABS-101, including in comparison to competitor molecules; technology development efforts and the application of those efforts, including acceleration of drug development timelines, reducing the time and costs related to drug development, advancements toward drug discovery and development activities, the success of our partnerships and their ability to generate scientific and technical insights for using AI drug creation to accelerate the development of candidate therapies, developing a diverse, high-value portfolio of novel drug treatments, and the anticipated value to us under our partnership, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities; replicating in clinical trials positive results found in preclinical studies; our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof; our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners; our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements; and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
What did Absci announce at the 42nd Annual J.P. Morgan Healthcare Conference?
How many antibody leads did Absci's generative AI platform design?
When does Absci expect to submit an IND for ABS-101?
What are the next steps for ABS-101 after the IND submission?
